Pacira BioSciences Inc (NASDAQ: PCRX). Important negative changes in fundamentals have recently occurred: the stock’s power rating fell below 50, significant quarterly earnings deceleration occurred, and the consensus estimate for December, 2026 decreased significantly.
Pacira BioSciences Inc (NASDAQ: PCRX). Important negative changes in investment behavior have recently occurred: the stock’s recent price decline challenged its longer term uptrend.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Pacira BioSciences has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Pacira BioSciences has a neutral Appreciation Score of 56 and a neutral Power Rating of 44, resulting in the Neutral Value Trend Rating.
Recent Price Action
Pacira BioSciences Inc (NASDAQ: PCRX) stock declined modestly by -1.0% on 10/7/25. The stock closed at $23.62. However, this decline was accompanied by normal trading volume at 83% of normal. The stock has performed in line with the market over the last nine months and has declined -6.8% during the last week.
Be the first to comment